SEC Form 4

FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden

0.5

hours per response:

Filed purpugat to Section 16(a) of the Securities Evolution Act of 102	л
Filed pursuant to Section 16(a) of the Securities Exchange Act of 193	4
or Section 20(h) of the Investment Company Act of 1040	

			.,	
1. Name and Address of Reporting Person [*] Lee Yuchun		Person [*]	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner
(Last)	(Last) (First) (Middle)			Officer (give title Other (specify below) below)
C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE		UTICALS	3. Date of Earliest Transaction (Month/Day/Year) 01/27/2023	
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
(Street)				X Form filed by One Reporting Person
BOSTON	MA	02210		Form filed by More than One Reporting Person
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)			Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code V		Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	01/27/2023		М		1,429	A	\$72.14	3,304	D		
Common Stock	01/27/2023		S ⁽¹⁾		379	D	\$321.31(2)(3)	2,925	D		
Common Stock	01/27/2023		S ⁽¹⁾		970	D	\$ 322.2 ⁽²⁾⁽⁴⁾	1,955	D		
Common Stock	01/27/2023		S ⁽¹⁾		80	D	\$323.33	1,875	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0.9.,	puis,	cuiis	, •••	manta	s, options			indes)				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$72.14	01/27/2023		М			1,429	(5)	05/31/2024	Common Stock	1,429	\$0.00	0	D	

Explanation of Responses:

1. Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.

2. Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

3. Open market sales reported on this line occurred at a weighted average price of \$321.31 (range \$320.62 to \$321.59).

4. Open market sales reported on this line occurred at a weighted average price of \$322.20 (range \$321.75 to \$322.74).

5. Fully vested.

Remarks:

<u>/s/ Christiana Stevenson,</u> <u>Attorney-in-Fact</u>

01/31/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.